MMP13 mediates cell cycle progression in melanocytes and melanoma cells: In vitro studies of migration and proliferation

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Meierjohann, Svenja ^a   Hufnagel, Anita ^a   Wende, Elisabeth ^a,b   Kleinschmidt, Markus A ^c   Wolf, Katarina ^d   Friedl, Peter ^d   Gaubatz, Stefan ^a   Schartl, Manfred ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBRILLAR COLLAGEN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL DEDIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOCYTE; MELANOMA; MOUSE; NONHUMAN; PROTEIN FUNCTION; SKIN CARCINOGENESIS; SKIN PIGMENTATION; CELL CYCLE; CELL DIFFERENTIATION; CELL MOTION; METABOLISM; PATHOLOGY;

CELL CYCLE; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; MATRIX METALLOPROTEINASE 13; MELANOCYTES; MELANOMA;

EID: 77954939848     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-201     Document Type: Article

References (59)

1. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006, 7:505-516. 10.1038/nrm1962, 16829981.
2. Ramnarain DB, Park S, Lee DY, Hatanpaa KJ, Scoggin SO, Otu H, Libermann TA, Raisanen JM, Ashfaq R, Wong ET, Wu J, Elliott R, Habib AA. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. Cancer Res 2006, 66:867-874. 10.1158/0008-5472.CAN-05-2753, 16424019.
3. Bardeesy N, Kim M, Xu J, Kim RS, Shen Q, Bosenberg MW, Wong WH, Chin L. Role of epidermal growth factor receptor signaling in RAS-driven melanoma. Mol Cell Biol 2005, 25:4176-4188. 10.1128/MCB.25.10.4176-4188.2005, 1087708, 15870287.
4. Lazar-Molnar E, Hegyesi H, Toth S, Falus A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 2000, 12:547-554. 10.1006/cyto.1999.0614, 10843728.
5. Tateishi M, Ishida T, Mitsudomi T, Kaneko S, Sugimachi K. Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res 1990, 50:7077-7080.
6. Ji H, Zhao X, Yuza Y, Shimamura T, Li D, Protopopov A, Jung BL, McNamara K, Xia H, Glatt KA, Thomas RK, Sasaki H, Horner JW, Eck M, Mitchell A, Sun Y, Al-Hashem R, Bronson RT, Rabindran SK, Discafani CM, Maher E, Shapiro GI, Meyerson M, Wong KK. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci USA 2006, 103:7817-7822. 10.1073/pnas.0510284103, 1456806, 16672372.
7. Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, Biegel JA, Hayes RL, Wong AJ. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 1995, 55:5536-5539.
8. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, Vogelstein B. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 1992, 89:2965-2969. 10.1073/pnas.89.7.2965, 48784, 1557402.
9. Meierjohann S, Mueller T, Schartl M, Buehner M. A structural model of the extracellular domain of the oncogenic EGFR variant Xmrk. Zebrafish 2006, 3:359-369. 10.1089/zeb.2006.3.359, 18377216.
10. Gomez A, Wellbrock C, Gutbrod H, Dimitrijevic N, Schartl M. Ligand-independent dimerization and activation of the oncogenic Xmrk receptor by two mutations in the extracellular domain. J Biol Chem 2001, 276:3333-3340. 10.1074/jbc.M006574200, 11038352.
11. Schartl M, Wilde B, Laisney JA, Taniguchi Y, Takeda S, Meierjohann S. A Mutated EGFR Is Sufficient to Induce Malignant Melanoma with Genetic Background-Dependent Histopathologies. J Invest Dermatol 2010, 130:249-258. 10.1038/jid.2009.213, 19609310.
12. Winnemoeller D, Wellbrock C, Schartl M. Activating mutations in the extracellular domain of the melanoma inducing receptor Xmrk are tumorigenic in vivo. Int J Cancer 2005, 117:723-729. 10.1002/ijc.21232, 15957173.
13. Wittbrodt J, Adam D, Malitschek B, Maueler W, Raulf F, Telling A, Robertson SM, Schartl M. Novel putative receptor tyrosine kinase encoded by the melanoma- inducing Tu locus in Xiphophorus. Nature 1989, 341:415-421. 10.1038/341415a0, 2797166.
14. Meierjohann S, Schartl M. From Mendelian to molecular genetics: the Xiphophorus melanoma model. Trends Genet 2006, 22:654-661. 10.1016/j.tig.2006.09.013, 17034900.
15. Wellbrock C, Weisser C, Geissinger E, Troppmair J, Schartl M. Activation of p59(Fyn) leads to melanocyte dedifferentiation by influencing MKP-1-regulated mitogen-activated protein kinase signaling. J Biol Chem 2002, 277:6443-6454. 10.1074/jbc.M110684200, 11734563.
16. Alanko T, Rosenberg M, Saksela O. FGF expression allows nevus cells to survive in three-dimensional collagen gel under conditions that induce apoptosis in normal human melanocytes. J Invest Dermatol 1999, 113:111-116. 10.1046/j.1523-1747.1999.00636.x, 10417628.
17. Geissinger E, Weisser C, Fischer P, Schartl M, Wellbrock C. Autocrine stimulation by osteopontin contributes to antiapoptotic signalling of melanocytes in dermal collagen. Cancer Res 2002, 62:4820-4828.
18. Martin MJ, Melnyk N, Pollard M, Bowden M, Leong H, Podor TJ, Gleave M, Sorensen PH. The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase. Mol Cell Biol 2006, 26:1754-1769. 10.1128/MCB.26.5.1754-1769.2006, 1430251, 16478996.
19. Giacobini P, Giampietro C, Fioretto M, Maggi R, Cariboni A, Perroteau I, Fasolo A. Hepatocyte growth factor/scatter factor facilitates migration of GN-11 immortalized LHRH neurons. Endocrinology 2002, 143:3306-3315. 10.1210/en.2002-220146, 12193542.
20. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999, 13:781-792.
21. Mook OR, Frederiks WM, Van Noorden CJ. The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 2004, 1705:69-89.
22. Rao JS, Bhoopathi P, Chetty C, Gujrati M, Lakka SS. MMP-9 short interfering RNA induced senescence resulting in inhibition of medulloblastoma growth via p16(INK4a) and mitogen-activated protein kinase pathway. Cancer Res 2007, 67:4956-4964. 10.1158/0008-5472.CAN-07-0380, 1905835, 17510426.
23. Nyalendo C, Beaulieu E, Sartelet H, Michaud M, Fontaine N, Gingras D, Beliveau R. Impaired tyrosine phosphorylation of membrane type 1-matrix metalloproteinase reduces tumor cell proliferation in three-dimensional matrices and abrogates tumor growth in mice. Carcinogenesis 2008, 29:1655-1664. 10.1093/carcin/bgn159, 18621744.
24. Meierjohann S, Wende E, Kraiss A, Wellbrock C, Schartl M. The oncogenic epidermal growth factor receptor variant xiphophorus melanoma receptor kinase induces motility in melanocytes by modulation of focal adhesions. Cancer Res 2006, 66:3145-3152. 10.1158/0008-5472.CAN-05-2667, 16540665.
25. Wolf K, Mazo I, Leung H, Engelke K, von Andrian UH, Deryugina EI, Strongin AY, Brocker EB, Friedl P. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J Cell Biol 2003, 160:267-277. 10.1083/jcb.200209006, 2172637, 12527751.
26. Sahai E, Marshall CJ. Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat Cell Biol 2003, 5:711-719. 10.1038/ncb1019, 12844144.
27. Han MY, Kosako H, Watanabe T, Hattori S. Extracellular signal-regulated kinase/mitogen-activated protein kinase regulates actin organization and cell motility by phosphorylating the actin cross-linking protein EPLIN. Mol Cell Biol 2007, 27:8190-8204. 10.1128/MCB.00661-07, 2169166, 17875928.
28. Mirmohammadsadegh A, Hassan M, Bardenheuer W, Marini A, Gustrau A, Nambiar S, Tannapfel A, Bojar H, Ruzicka T, Hengge UR. STAT5 phosphorylation in malignant melanoma is important for survival and is mediated through SRC and JAK1 kinases. J Invest Dermatol 2006, 126:2272-2280. 10.1038/sj.jid.5700385, 16741510.
29. Hofmann UB, Houben R, Brocker EB, Becker JC. Role of matrix metalloproteinases in melanoma cell invasion. Biochimie 2005, 87:307-314. 10.1016/j.biochi.2005.01.013, 15781317.
30. Blackburn JS, Rhodes CH, Coon CI, Brinckerhoff CE. RNA interference inhibition of matrix metalloproteinase-1 prevents melanoma metastasis by reducing tumor collagenase activity and angiogenesis. Cancer Res 2007, 67:10849-10858. 10.1158/0008-5472.CAN-07-1791, 18006830.
31. Huntington JT, Shields JM, Der CJ, Wyatt CA, Benbow U, Slingluff CL, Brinckerhoff CE. Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. J Biol Chem 2004, 279:33168-33176. 10.1074/jbc.M405102200, 15184373.
32. Goerge T, Barg A, Schnaeker EM, Poppelmann B, Shpacovitch V, Rattenholl A, Maaser C, Luger TA, Steinhoff M, Schneider SW. Tumor-derived matrix metalloproteinase-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation. Cancer Res 2006, 66:7766-7774. 10.1158/0008-5472.CAN-05-3897, 16885380.
33. Shellman YG, Makela M, Norris DA. Induction of secreted matrix metalloproteinase-9 activity in human melanoma cells by extracellular matrix proteins and cytokines. Melanoma Res 2006, 16:207-211. 10.1097/01.cmr.0000215033.92693.73, 16718267.
34. Gadea G, de Toledo M, Anguille C, Roux P. Loss of p53 promotes RhoA-ROCK-dependent cell migration and invasion in 3D matrices. J Cell Biol 2007, 178:23-30. 10.1083/jcb.200701120, 2064414, 17606864.
35. Schor SL, Allen TD, Harrison CJ. Cell migration through three-dimensional gels of native collagen fibres: collagenolytic activity is not required for the migration of two permanent cell lines. J Cell Sci 1980, 46:171-186.
36. Wolf K, Wu YI, Liu Y, Geiger J, Tam E, Overall C, Stack MS, Friedl P. Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol 2007, 9:893-904. 10.1038/ncb1616, 17618273.
37. Tardif G, Reboul P, Pelletier JP, Martel-Pelletier J. Ten years in the life of an enzyme: the story of the human MMP-13 (collagenase-3). Mod Rheumatol 2004, 14:197-204. 10.1007/s10165-004-0292-7, 17143675.
38. Inada M, Wang Y, Byrne MH, Rahman MU, Miyaura C, Lopez-Otin C, Krane SM. Critical roles for collagenase-3 (Mmp13) in development of growth plate cartilage and in endochondral ossification. Proc Natl Acad Sci USA 2004, 101:17192-17197. 10.1073/pnas.0407788101, 535367, 15563592.
39. Knauper V, Lopez-Otin C, Smith B, Knight G, Murphy G. Biochemical characterization of human collagenase-3. J Biol Chem 1996, 271:1544-1550. 10.1074/jbc.271.3.1544, 8576151.
40. Deng SJ, Bickett DM, Mitchell JL, Lambert MH, Blackburn RK, Carter HL, Neugebauer J, Pahel G, Weiner MP, Moss ML. Substrate specificity of human collagenase 3 assessed using a phage-displayed peptide library. J Biol Chem 2000, 275:31422-31427. 10.1074/jbc.M004538200, 10906330.
41. Song RX, Zhang Z, Chen Y, Bao Y, Santen RJ. Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells. Endocrinology 2007, 148:4091-4101. 10.1210/en.2007-0240, 2727866, 17525128.
42. Sadowski T, Dietrich S, Koschinsky F, Sedlacek R. Matrix metalloproteinase 19 regulates insulin-like growth factor-mediated proliferation, migration, and adhesion in human keratinocytes through proteolysis of insulin-like growth factor binding protein-3. Mol Biol Cell 2003, 14:4569-4580. 10.1091/mbc.E03-01-0009, 266773, 12937269.
43. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000, 14:163-176. 316345, 10652271.
44. Fowlkes JL, Serra DM, Nagase H, Thrailkill KM. MMPs are IGFBP-degrading proteinases: implications for cell proliferation and tissue growth. Ann N Y Acad Sci 1999, 878:696-699. 10.1111/j.1749-6632.1999.tb07765.x, 10415811.
45. Manes S, Mira E, Barbacid MM, Cipres A, Fernandez-Resa P, Buesa JM, Merida I, Aracil M, Marquez G, Martinez AC. Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J Biol Chem 1997, 272:25706-25712. 10.1074/jbc.272.41.25706, 9325295.
46. Suzuki M, Raab G, Moses MA, Fernandez CA, Klagsbrun M. Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J Biol Chem 1997, 272:31730-31737. 10.1074/jbc.272.50.31730, 9395517.
47. Levi E, Fridman R, Miao HQ, Ma YS, Yayon A, Vlodavsky I. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci USA 1996, 93:7069-7074. 10.1073/pnas.93.14.7069, 38937, 8692946.
48. P OC, Rhys-Evans P, Eccles S. A synthetic matrix metalloproteinase inhibitor prevents squamous carcinoma cell proliferation by interfering with epidermal growth factor receptor autocrine loops. Int J Cancer 2002, 100:527-533. 10.1002/ijc.10531, 12124801.
49. Hashimoto G, Inoki I, Fujii Y, Aoki T, Ikeda E, Okada Y. Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165. J Biol Chem 2002, 277:36288-36295. 10.1074/jbc.M201674200, 12114504.
50. D'Angelo M, Billings PC, Pacifici M, Leboy PS, Kirsch T. Authentic matrix vesicles contain active metalloproteases (MMP). a role for matrix vesicle-associated MMP-13 in activation of transforming growth factor-beta. J Biol Chem 2001, 276:11347-11353. 10.1074/jbc.M009725200, 11145962.
51. Tarin C, Gomez M, Calvo E, Lopez JA, Zaragoza C. Endothelial nitric oxide deficiency reduces MMP-13-mediated cleavage of ICAM-1 in vascular endothelium: a role in atherosclerosis. Arterioscler Thromb Vasc Biol 2009, 29:27-32. 10.1161/ATVBAHA.108.169623, 18988893.
52. Dreier R, Grassel S, Fuchs S, Schaumburger J, Bruckner P. Pro-MMP-9 is a specific macrophage product and is activated by osteoarthritic chondrocytes via MMP-3 or a MT1-MMP/MMP-13 cascade. Exp Cell Res 2004, 297:303-312. 10.1016/j.yexcr.2004.02.027, 15212936.
53. Xu D, Suenaga N, Edelmann MJ, Fridman R, Muschel RJ, Kessler BM. Novel MMP-9 substrates in cancer cells revealed by a label-free quantitative proteomics approach. Mol Cell Proteomics 2008, 7:2215-2228. 10.1074/mcp.M800095-MCP200, 2577209, 18596065.
54. Corte MD, Gonzalez LO, Corte MG, Quintela I, Pidal I, Bongera M, Vizoso F. Collagenase-3 (MMP-13) expression in cutaneous malignant melanoma. Int J Biol Markers 2005, 20:242-248.
55. Zigrino P, Kuhn I, Bauerle T, Zamek J, Fox JW, Neumann S, Licht A, Schorpp-Kistner M, Angel P, Mauch C. Stromal Expression of MMP-13 Is Required for Melanoma Invasion and Metastasis. J Invest Dermatol 2009, 129:2686-2693. 10.1038/jid.2009.130, 19516266.
56. Nuti E, Casalini F, Avramova SI, Santamaria S, Cercignani G, Marinelli L, La Pietra V, Novellino E, Orlandini E, Nencetti S, Tuccinardi T, Martinelli A, Lim NH, Visse R, Nagase H, Rossello A. N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis. J Med Chem 2009, 52:4757-4773. 10.1021/jm900261f, 19606871.
57. Johnson AR, Pavlovsky AG, Ortwine DF, Prior F, Man CF, Bornemeier DA, Banotai CA, Mueller WT, McConnell P, Yan C, et al. Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. J Biol Chem 2007, 282:27781-27791. 10.1074/jbc.M703286200, 17623656.
58. Jungel A, Ospelt C, Lesch M, Thiel M, Sunyer T, Schorr O, Michel BA, Gay RE, Kolling C, Flory C, Gay S, Neidhart M. Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritis. Ann Rheum Dis 2009, 69:898-902. 10.1136/ard.2008.106021, 19497915.
59. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002, 30:e36. 10.1093/nar/30.9.e36, 113859, 11972351.